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Identity 
Other names: FRP1, MEC1, SCKL, SCKL1 
HGNC (Hugo): ATR 
Location: 3q23 
Local order 
According to NCBI Map Viewer (ATR), genes 
(pseudogenes and hypothetical proteins have been 
excluded) flanking ATR in telomere to centromere 
direction on 3q23 are: SLC9A9 (solute carrier family 9 
(sodium/hydrogen exchanger), member 9), CHST2 
(carbohydrate (N-acetylglucosamine-6-O) 
sulfotransferase 2), SR140 (U2-associated SR140 
protein), PAQR9 (progestin and adipo Q receptor 
family member IX), PCOLCE2 (procollagen C-
endopeptidase enhancer 2), TRPC1 (transient receptor 
potential cation channel, subfamily C, member 1), 
PLS1 (plastin I (I isoform)), ATR. 
Note 
ATR is a serine/threonine kinase and belongs to the 
phosphoinositide 3- kinase related protein kinases 
(PIKKs), particularly to ATM (ataxia telangiectasia 
mutated) subfamily. It functions to maintain genome 
integrity by stabilizing replication forks and by 
regulating cell cycle progression and DNA repair. 
ATR, in a complex with its regulatory partner ATRIP 
(ATR interacting protein), localises to stalled 
replication forks responding to a variety of types of 
replication stress and DNA damage. Recipients of ATR 
signalling are a plethora of substrates among them 
DNA damage protein sensors, mediators and effectors, 
DNA repair proteins, proteins of replisome and 
chromatin remodelling as well as centrosomal proteins. 
ATR function is essential for cell viability and 
disruptions of ATR signalling cause genomic 
instability. Mutations in ATR gene are rare and 
compatible with life only when hypomorphic or 
heterozygous. A clear link between disease and ATR 
gene mutation is the Seckel syndrome, while ATR has 
been proposed to serve as a haploinsufficient tumor 
suppressor in some types of cell deficiencies and its 
activation has been detected in most cancer 
chemotherapies. 




The first human ATR cDNA full-length clone 
(originally named FRP1, FRAP-related protein 1) was 
isolated from a Jurkat T-cell cDNA library and 
identified by its significant homology to other members 
of the phosphatidylinositol kinase-related kinase 
(PIKK) family. Evidence for the existence of two 
alternative ATR transcripts, with differential tissue 
expression, in the non-catalytic domain has been 
reported, by using RT-PCR. Transcript variants 
utilizing alternative polyadenylation signals are also 
exist. ATR gene has recently been annotated in the 
Ensembl database. 
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Intron/Exon structure of the ATR gene (ENSG00000175054). There are two transcript isoforms of this gene, with 47 and 46 exons, 
respectively, spanning to an area of 129.59 kb. Exons are illustrated with vertical lines and boxes (A, B). Diagram in panel B represents 
only the exons' structure. Direction of transcription is shown by an arrow. The 6th exon that is missing from ATR isoform 2 is indicated 
with an asterisk (A) or with blue colour box (B). Untranslated regions are in light pink, while coding regions are in deep pink. Start of 
translation (ATG) and stop codon (TGA) are also indicated. 
 
Description 
47 exons spanning to 129.59 kb. 
Transcription 
Two isoforms: isoform ATR-201 (ENST00000350721) 
(8248 bp) includes all 47 exons, while isoform ATR-
202 (ENST00000383101) (8056 bp) does not include 
exon 6, deleting 192 nt (64 codons) from the mRNA. 
The translation start site is in exon 1. 
Protein 
Note 
ATR and ATM function in an overlapping, but non-
redundant fashion, phosphorylating many of the same 
substrates. However, and in contrast to ATM, ATR's 
function is essential for cell viability. ATR-deficiency 
at the organismal level affects normal development, 
tissue homeostasis, and ageing. 
Description 
Isoform ATR-201 (ENSP00000343741): 2644 amino 
acids (predicted MW 301365.74 Da).  
Isoform ATR-202 (ENSP00000372581): 2580 aa 
(predicted MW 294218.33 Da).  
Biochemical studies of ATR protein do not distinguish 
between the two different isoforms. 
ATR protein contains a PI3/4 kinase catalytic domain, 
1 FAT domain, 1 FATC domain, 1 UME domain, and 2 
HEAT repeats. 
Expression 
Isoform 1 has ubiquitous expression with highest levels 
in testis. Isoform 2 has more specific expression (has 
found in pancreas, liver and placenta while is not 
detected in heart, testis and ovary).  
Forced expression of ATR inhibits MyoD function, 
leading to loss of differentiation, as well as induces 
cell-cycle abnormalities (increased aneuploidy and 
elimination of IR-induced G1 arrest). Limited 
expression of ATR or overexpression of kinase dead 
forms of this protein increases cell sensitivity to a 
variety of DNA damage agents and replication 
inhibitors, such as ionizing radiation (IR), cis-platinum, 
hydroxy urea (HU), methylmethanesulfonate (MMS) 
and ultra violet (UV) irradiation, leading to significant 
losses in checkpoint control and cell viability. Loss of 
ATR results in DNA fragile site expression, a specific 
type of genomic instability. 
Localisation 
In the nucleus, where it is recruited to chromatin during 
S-phase and redistributes to distinct foci upon DNA 
damage, stalling of replication forks with replicaton 
inhibitors or hypoxia. ATR has also been found in PML 
(promyetocytic leukaemia protein) nuclear bodies of 
some types of cells.  
Kinase dead forms of ATR do not relocalize in 
response to IR and block nuclear translocation of RPA 
complex in a cell cycle-dependent manner. 
Function 
ATR essential maintains genome integrity by serving 
multiple roles in the cellular response to DNA damage 
and endogenous replication stress. It signals to regulate 
the firing of replication origins, the repair of dam ged 
replication forks and to prevent the premature mitotic 
entry. Moreover, it critically functions directly at the 
sites of stalled forks by stabilizing components of the 
replisome to ensure completion of replication during 
recovery of stalled forks. 
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ATR-mediated activation of S-phase checkpoint 
ATR is activated during every S-phase and in respone 
to many different types of damage, including double 
strand breaks (DSB), base adducts, crosslinks and 
replication stress. The structural requirement for ATR 
activation is a RPA-coated single-stranded DNA with a 
5' double stranded primer junction. ATR recognition of 
the above DNA structure depends upon a protein co-
factor, ATRIP (ATR-interacting protein), that regulates 
ATR localization and activation. The activity of ATR-
ATRIP complex is directly stimulated by TOPBP1 
(DNA topoisomerase II binding protein 1), which 
recruitment to DNA is facilitated by the 9-1-1 (Rad9-
Rad1-Hus1) checkpoint clamp. 
Activated ATR signals to coordinate cell cycle 
transitions and repair through the phosphorylation of 
numerous of substrates including RAD17, p53, 
TopBP1 (via a feed-forward signalling loop that 
amplifies ATR-mediated signals), the mediator protein 
CEP164 and the downstream effector Chk1 (checkpoint 
kinase 1), which is the best characterized target of the 
ATR activity. Recombination proteins BRCA1 (breast 
cancer susceptibility gene 1), WRN (Werner's 
syndrome helicase), and BLM (Bloom's syndrome 
helicase) are ATR sunstrates as well. ATR also 
phosphorylates the Fanconi-anemia protein FANCD2 
to regulate inter-strand crosslink repair as well as the 
nucleotide excision repair protein XPA to regulate its 
intracellular localization. Moreover, ATR interacts with 
the mismatch repair protein MSH2 (mutS homolog 2) 
to form a signalling module and regulate the 
phosphorylation of Chk1 and SMC1 (structure 
maintenance of chromosome 1). Upon replication stres  
ATR also phosphorylates the Ser-139 of 
H2AX/H2AFX, while is associated with the tyrosine 
kinase oncogene BCR-ABL after genotoxic stress. 
ATR-mediated stabilization of replication forks 
ATR has a crucial role in the maintenance of functional 
replication forks independent of its function in the 
activation of Rad53 (yeast homolog of checkpoint 
kinase 2). Among substrates of ATR on the replication 
forks are the proteins RPA1, RPA2, MCM2-7 
(minichromosome maintenance 2-7) complex, 
MCM10, PCNA, replication factor C, Tim (Timeless)-
Tipin complex, SMARCAL1 (HARP)-a SNF2 ATP-
dependent annealing helicase, and several polymerases, 
such as Pol alpha and Pol epsilon. Furthermore, a key 
target of ATR-ATRIP complex is Claspin, and is 
important both for S-phase checkpoint activation (via 
regulation of Chk1 phosphorylation) but also for 
replication forks stabilization (via interactions with Pol 
epsilon) even in normal cycling cells. ATR is found 
also associated with two components of the 
nucleosome remodelling and deacetylating complex, 
the chromodomain-helicase-DNA-binding protein 4 
(CHD4) and the histone-deacetylase-2 (HDAC2). 
ATR also functions to stabilize fragile sites. In effect of 
all the above, the ATR's essential function for cell 
viability may be to respond to abundant sources of 
replication stress in normal cycling cells as well as after 
exposure to DNA damage agents. 
ATR implication in centrosomal function via: 
(a) Direct interaction with NBS1 (Nijmegen breakage 
syndrome 1) and BRCA1 pathway. 
(b) Signalling to Chk1 and control of centrosome 
overduplication after DNA damage. 
(c) Direct phosphorylation and delocalization from 
centrosome of CEP63 in the presence of chromosomal 
breaks. 
Homology 
According to HomoloGene (NCBI), homologs of the 
human ATR gene (NP_001175.2, 2644 aa) are the 
followings: 
- Chimpanzee (Pan troglodytes) XP_516792.2, 2646 aa 
- Dog (Canis lupus familiaris) XP_534295.2, 2644 aa 
- Cattle (Bos taurus) XP_581054.3, 2644 aa 
- Rat (Rattus norvegicus) XP_001062084.1, 2166 aa 
- Zebrafish (Danio rerio) XP_696163.3, 2638 aa 
Mutations 
Somatic 
Single nucleotide substitutions have been described n 
various types of carcinomas at total frequency 2%, 
mostly in heterozygous form. In particular, missense 
mutations have been found in the PI3/4 kinase catalytic 
domain and in FAT domain of breast and lung cancers 
respectively. Coding silent mutations have also been 
detected in carcinomas of stomach, breast, skin and 
central nervous system. 
Implicated in 
ATR haploinsufficiency in mismatch 
repair (MMR)-deficient cancers 
Note 
Homozygous null mutations of ATR have not been 
reported in human cancers even in late-stage malignant 
cells and it is unlikely to exist given that mutations in 
both alleles of ATR gene lead to cell lethality. 
However, ATR gene has a potential increased 
susceptibility to somatic mutations in tumors with 
defective MMR, due to the presence of an A10 
mononucleotide repeat in the exon 10 protein coding 
region. In particular, clinical reports have demonstrated 
that ATR is heterozygously mutated in certain types of 
tumors with mismatch repair deficiencies, including 
malignancies of the colon, the stomach and the 
endometrium. Although, it is not well understood how 
these mutations could contribute to the tumorigenic 
process, lines of evidence suggest that ATR serves as a 
haploinsufficient tumor suppressor in mismatch repair-
deficient cells. Disruption of a single ATR allele g ne 
in MLH1-deficient background significantly increases 
fragile site expression, chromosomal amplifications a d 
rearrangements. The above chromosomal instability 
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accompanied by hypersensitivity to genotoxic stress 
agents, such as hydroxyurea. Furthermore, mice with
ATR+/- MLH1-/- genotype are more prone to early 
tumor development compared with ATR+/- or MLH1-
/- counterparts. More recently has been reported that 
the combined ATR haploinsufficiency and MMR-
deficiency that lead to chromosomal instability in colon 
cancer cells are also enhance the sensitivity of these 
cells to chemotherapeutic agent 5-fluorouracil, a 
standard treatment for colorectal cancers. The 
mechanism by which this occurs remains unclear. 
However, some findings suggest that MMR-deficient 
cells with partial reduced ATR activity are more prone 
to formation of DNA double strand breaks (DSBs). 
Additionally, partial inhibition of ATR has been 
reported to be significant for treatment of patients with 
high-microsatellite instability (MSI, a class of genomic 
instability clinically distinct from chromosome 
instability that is the result of mutations in MMR 
machinery) colorectal tumors increasing the disease-
free survival time. 
Prognosis 
Recent works have demonstrated that high-MSI 
endometrioid endometrial cancers harboring ATR 
mutations have worse survival compared to ATR wild-
type high-MSI tumors, suggesting that the last ones 
might also have an improved prognosis compared to 
microsatellite stable (MSS) endometrial tumors. 
However, the prognostic significance of ATR 
mutations in MMR deficient cancers remains to be 
clarified. 
Cytogenetics 
ATR partial knockdown in colon cancer cell lines with 
defective MMR leads to the formation of chromosomal 
breaks and gaps, chromosome bridges and micronuclei, 
as well as to the formation of supernumerary 
centrosomes. 
ATR-mutated Seckel syndrome (ATR-
SS) 
Note 
Seckel syndrome is a rare autosomal recessive disorder 
characterised by severe intrauterine growth retardaion, 
profound microcephaly, dwarfism, mental retardation 
and isolated skeletal abnormalities. At least four 
distinct Seckel syndrome-causative genomic loci (Skl 
1-4) have been identified but only two genetic defects 
are known in this disorder. Both of them impacting on 
ATR-dependent DNA damage signalling. The first 
identified defect was in ATR gene itself, concerning a 
hypomorphic single synonymous mutation (A>G 2101) 
that caused aberrant splicing of ATR. Pericentrin 
(PCNT), a core structural component of centrosomes, 
has also been identified as Seckel syndrome-causative 
gene. 
Cytogenetics 
Cells from ATR-SS patients exhibit increased  
sensitivity to DNA replication fork stalling (measured 
as nuclear fragmentation and micronucleus formation), 
impaired phosphorylation of ATR substrates, defectiv  
G2/M arrest and supernumerous mitotic centrosomes. 
Impaired ATR signalling is also characteristic of cells 
derived from other disorders with microcephaly and 
growth delay such as pericentrin-mutated Seckel 
syndrome (PCNT-SS), primary autosomal recessive 
microcephaly (MCPH) and Nijmegen breakage 
syndrome. 
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